# GRCE — Grace Therapeutics Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** GRCE  
**Sources:** 14  
**Published:** 2026-11-01  
**Canonical:** https://app.k3vl4r.com/research/deep-research-grce-grace-therapeutics-inc-catalysts-narrative-risks-10573

---

## Company Snapshot

Grace Therapeutics, Inc. (Nasdaq: GRCE) is a late-stage, clinical-phase biopharma company headquartered in Princeton, New Jersey, formerly known as Acasti Pharma Inc. (renamed October 2024) [[9]](https://www.gracetx.com/investors)[[11]](https://investingcalendar.com/stock/xnas/grce). It develops drug-delivery technologies for rare and orphan diseases, with lead candidate GTx-104, an injectable (IV) formulation of nimodipine for aneurysmal subarachnoid hemorrhage (aSAH) [[6]](https://www.theglobeandmail.com/investing/markets/stocks/GRCE/pressreleases/36587264/grace-therapeutics-announces-abstract-highlighting-strive-on-phase-3-trial-results-accepted-for-presentation-at-aan-2026/)[[8]](https://www.marketbeat.com/earnings/reports/2026-11-12-grace-therapeutics-inc-stock/). As of late October 2026 the stock closed near $1.94 with a market capitalization of roughly $44M [[1]](https://catalystalert.io/research/GRCE)[[8]](https://www.marketbeat.com/earnings/reports/2026-11-12-grace-therapeutics-inc-stock/). Its fiscal year ends March 31 [[9]](https://www.gracetx.com/investors)[[11]](https://investingcalendar.com/stock/xnas/grce).

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-grce-grace-therapeutics-inc-catalysts-narrative-risks-10573 (free to sign up)._